Jefferies Group’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $7.24M | Buy |
65,500
+35,500
| +118% | +$3.58M | 0.06% | 267 |
|
|
2022
Q2 | $2.25M | Hold |
30,000
| – | – | 0.02% | 581 |
|
|
2022
Q1 | $2.34M | Sell |
30,000
-141,400
| -82% | -$10.8M | 0.01% | 633 |
|
|
2021
Q4 | $15.4M | Buy |
+171,400
| New | +$14.7M | 0.09% | 185 |
|
|
2021
Q3 | – | Sell |
-22,000
| Closed | -$1.71M | – | 1998 |
|
|
2021
Q2 | $1.71M | Sell |
22,000
-3,000
| -12% | -$227K | 0.01% | 800 |
|
|
2021
Q1 | $1.86M | Buy |
+25,000
| New | +$2.31M | 0.02% | 713 |
|
|
2020
Q1 | – | Sell |
-38,900
| Closed | -$5.02M | – | 2629 |
|
|
2019
Q4 | $5.02M | Sell |
38,900
-316,800
| -89% | -$32M | 0.04% | 515 |
|
|
2019
Q3 | $26.8M | Buy |
355,700
+203,600
| +134% | +$24M | 0.21% | 57 |
|
|
2019
Q2 | $23.1M | Sell |
152,100
-113,700
| -43% | -$13.8M | 0.17% | 85 |
|
|
2019
Q1 | $31.7M | Buy |
265,800
+255,400
| +2,456% | +$32.8M | 0.26% | 43 |
|
|
2018
Q4 | $1.14M | Hold |
10,400
| – | – | 0.01% | 1089 |
|
|
2018
Q3 | $1.68M | Sell |
10,400
-33,800
| -76% | -$4.62M | 0.01% | 1063 |
|
|
2018
Q2 | $5.84M | Buy |
+44,200
| New | +$4.17M | 0.03% | 459 |
|
|
2018
Q1 | – | Sell |
-50,400
| Closed | -$2.8M | – | 2682 |
|
|
2017
Q4 | $2.8M | Buy |
50,400
+100
| +0.2% | +$5.3K | 0.01% | 822 |
|
|
2017
Q3 | $2.28M | Sell |
50,300
-21,400
| -30% | -$855K | 0.02% | 881 |
|
|
2017
Q2 | $2.42M | Sell |
71,700
-104,900
| -59% | -$3.42M | 0.02% | 865 |
|
|
2017
Q1 | $5.23M | Sell |
176,600
-88,800
| -33% | -$2.75M | 0.04% | 484 |
|
|
2016
Q4 | $7.28M | Sell |
265,400
-243,400
| -48% | -$9.78M | 0.04% | 435 |
|
|
2016
Q3 | $31.2M | Sell |
508,800
-1,735,500
| -77% | -$52.5M | 0.16% | 98 |
|
|
2016
Q2 | $42.8M | Buy |
2,244,300
+2,053,300
| +1,075% | +$38M | 0.19% | 62 |
|
|
2016
Q1 | $3.73M | Buy |
191,000
+16,000
| +9% | +$280K | 0.02% | 594 |
|
|
2015
Q4 | $6.75M | Sell |
175,000
-84,100
| -32% | -$2.73M | 0.04% | 358 |
|
|
2015
Q3 | $8.32M | Buy |
259,100
+68,000
| +36% | +$2.31M | 0.05% | 311 |
|
|
2015
Q2 | $5.82M | Buy |
+191,100
| New | +$3.91M | 0.03% | 461 |
|
|
2015
Q1 | – | Sell |
-517,400
| Closed | -$7.49M | – | 2361 |
|
|
2014
Q4 | $7.49M | Buy |
517,400
+192,400
| +59% | +$3.26M | 0.04% | 319 |
|
|
2014
Q3 | $6.86M | Buy |
325,000
+227,600
| +234% | +$5.14M | 0.05% | 332 |
|
|
2014
Q2 | $2.9M | Sell |
97,400
-60,500
| -38% | -$1.91M | 0.02% | 512 |
|
|
2014
Q1 | $3.79M | Sell |
157,900
-303,200
| -66% | -$7.73M | 0.04% | 395 |
|
|
2013
Q4 | $9.39M | Buy |
461,100
+249,800
| +118% | +$7.42M | 0.06% | 176 |
|
|
2013
Q3 | $9.98M | Buy |
211,300
+83,200
| +65% | +$3.2M | 0.1% | 181 |
|
|
2013
Q2 | $4.87M | Buy |
+128,100
| New | +$4.58M | 0.05% | 265 |
|
Other funds holding SRPT
ACA
EC
Jefferies Group's SRPT Position: Q3 2022 in Review
Jefferies Group reduced its Sarepta Therapeutics (SRPT) stake by 33% in Q3 2022, selling an estimated $2.92M and leaving 57,628 shares worth $6.37M. The position accounts for 0.05% of the portfolio, ranked #297.
Jefferies Group first reported a position in SRPT in Q2 2013 and has held it in 31 quarters since. The position peaked at $142M in Q3 2016. 375 funds tracked by Wall St. Rank hold SRPT as of Q3 2022.
- Jefferies Group held 57,628 shares of Sarepta Therapeutics worth $6.37M as of Q3 2022.
- Jefferies Group sold 28,991 Sarepta Therapeutics shares in Q3 2022, an estimated $2.92M.
- Sarepta Therapeutics made up 0.05% of Jefferies Group's portfolio in Q3 2022, its #297 holding.
- Jefferies Group first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 31 quarters since.
- Jefferies Group's Sarepta Therapeutics position peaked at $142M in Q3 2016.
- 375 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2022.
Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.